Literature DB >> 22679906

Prognostic indicators of survival in patients with compensated and decompensated cirrhosis.

Alexander Zipprich1, Guadalupe Garcia-Tsao, Sebastian Rogowski, Wolfgang E Fleig, Thomas Seufferlein, Matthias M Dollinger.   

Abstract

BACKGROUND/AIMS: Patients with cirrhosis are classified in a compensated and a decompensated stage. Portal hypertension is responsible for most of the complications of cirrhosis that mark the transition from compensated to decompensated cirrhosis. The objectives of this study were (a) to analyse survival of the different stages and substages of cirrhosis and (b) to examine the prognostic value of the hepatic venous pressure gradient (HVPG) at each of the stages.
METHODS: A total of 729 patients with suspected cirrhosis underwent routine measurement of portal pressure and systemic haemodynamics between 11/1995 and 12/2004. The primary end-point of the study was death, collected until November 30th, 2006. Multivariable analysis was performed using two models to determine predictors of death at each stage.
RESULTS: A total of 443 patients were included in the study. The 1-year mortality was 5.4% in compensated and 20.2% in decompensated patients. Compensated patients in stage 1 (no varices) had a longer survival than stage 2 patients (varices present) (P = 0.015). In decompensated patients, survival was not different between stage 3 (ascites, with or without varices) and stage 4 (variceal haemorrhage, with or without ascites). Age and HVPG (cut-off 10 mmHg) were independent predictors of death in compensated patients, whereas MELD was in decompensated patients.
CONCLUSION: Survival rates and predictors of death are different between patients with compensated and decompensated cirrhosis. Unlike the Italian cohort staging system, ascites is a better stratifying clinical event than variceal haemorrhage in patients with decompensated cirrhosis. The presence of clinically significant portal hypertension has prognostic value in compensated cirrhosis.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2012        PMID: 22679906      PMCID: PMC3713489          DOI: 10.1111/j.1478-3231.2012.02830.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  19 in total

Review 1.  The hepatic venous pressure gradient: anything worth doing should be done right.

Authors:  Roberto J Groszmann; Suchat Wongcharatrawee
Journal:  Hepatology       Date:  2004-02       Impact factor: 17.425

2.  Management of adult patients with ascites due to cirrhosis.

Authors:  Bruce A Runyon
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

Review 3.  Management of complications of cirrhosis in patients awaiting liver transplantation.

Authors:  Andres Cardenas; Pere Ginès
Journal:  J Hepatol       Date:  2004-12-24       Impact factor: 25.083

Review 4.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.

Authors:  Gennaro D'Amico; Guadalupe Garcia-Tsao; Luigi Pagliaro
Journal:  J Hepatol       Date:  2005-11-09       Impact factor: 25.083

5.  Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension.

Authors:  Roberto de Franchis
Journal:  J Hepatol       Date:  2005-07       Impact factor: 25.083

6.  Survival and prognostic indicators in compensated and decompensated cirrhosis.

Authors:  G D'Amico; A Morabito; L Pagliaro; E Marubini
Journal:  Dig Dis Sci       Date:  1986-05       Impact factor: 3.199

7.  Improved survival after variceal bleeding in patients with cirrhosis over the past two decades.

Authors:  Nicolas Carbonell; Arnaud Pauwels; Lawrence Serfaty; Olivier Fourdan; Victor George Lévy; Raoul Poupon
Journal:  Hepatology       Date:  2004-09       Impact factor: 17.425

8.  Compensated cirrhosis: natural history and prognostic factors.

Authors:  P Ginés; E Quintero; V Arroyo; J Terés; M Bruguera; A Rimola; J Caballería; J Rodés; C Rozman
Journal:  Hepatology       Date:  1987 Jan-Feb       Impact factor: 17.425

9.  Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.

Authors:  Cristina Ripoll; Roberto Groszmann; Guadalupe Garcia-Tsao; Norman Grace; Andrew Burroughs; Ramon Planas; Angels Escorsell; Juan Carlos Garcia-Pagan; Robert Makuch; David Patch; Daniel S Matloff; Jaime Bosch
Journal:  Gastroenterology       Date:  2007-05-21       Impact factor: 22.682

10.  Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial.

Authors:  Jaime Bosch; Dominique Thabut; Agustín Albillos; Nicolas Carbonell; Julius Spicak; Julien Massard; Gennaro D'Amico; Didier Lebrec; Roberto de Franchis; Søren Fabricius; Yan Cai; Flemming Bendtsen
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

View more
  72 in total

Review 1.  Outcomes in Clinical Trials Evaluating Interventions for the Prevention and Treatment of Hepatic Encephalopathy.

Authors:  Lise L Gluud; Rebecca Jeyaraj; Marsha Y Morgan
Journal:  J Clin Exp Hepatol       Date:  2019-02-15

Review 2.  Could there be light at the end of the tunnel? Mesocaval shunting for refractory esophageal varices in patients with contraindications to transjugular intrahepatic portosystemic shunt.

Authors:  Jessica Davis; Albert K Chun; Marie L Borum
Journal:  World J Hepatol       Date:  2016-07-08

3.  Hepatocellular carcinoma surveillance: the often-neglected practice.

Authors:  Jennifer Sammon; Korosh Khalili
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

4.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

5.  Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.

Authors:  Harry D Zacharias; Antony P Zacharias; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2019-06-17

Review 6.  Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.

Authors:  Lise Lotte Gluud; Hendrik Vilstrup; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2016-05-06

7.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.

Authors:  Arun J Sanyal; Scott L Friedman; Arthur J McCullough; Lara Dimick-Santos
Journal:  Hepatology       Date:  2015-03-19       Impact factor: 17.425

8.  Clinical presentation and survival of Asian and non-Asian patients with HCV-related hepatocellular carcinoma.

Authors:  Benjamin Yip; James M Wantuck; Lily H Kim; Robert J Wong; Aijaz Ahmed; Gabriel Garcia; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2013-11-27       Impact factor: 3.199

Review 9.  Outcomes of transjugular intrahepatic portosystemic shunts for ascites.

Authors:  Zachary L Bercu; Aaron M Fischman
Journal:  Semin Intervent Radiol       Date:  2014-09       Impact factor: 1.513

Review 10.  Clinical Assessment and Management of Portal Hypertension.

Authors:  Jacob Kibrit; Ruben Khan; Barbara H Jung; Sean Koppe
Journal:  Semin Intervent Radiol       Date:  2018-08-06       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.